BEIJING, China. Sino Biological, Inc.(„Sino Biological“ or the „Company”), a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext (SZSE: 301047), specializing in biological research reagents and related technical contract research services, has successfully concluded its acquisition of Vancouver-based Canadian biotechnology company SignalChem Biotech Inc. (“SCB” or „SignalChem”). Sino Biological has acquired 100% of SCB shares in a deal valued at $48M USD, inclusive of all assets, assumed indebtedness, and net of cash deposits.   Sino Biological Finalizes the Acquisition of SignalChem Biotech, Strengthening Global Presence and Expanding Product Portfolio

CAR T cell therapy has proven effective in treating various haematological cancers. However, not all patients respond equally well to treatment. In a recent clinical study, researchers from the University of Leipzig Medical Center and the Fraunhofer Institute for Cell Therapy and Immunology identified several biomarkers that are associated with the response to CAR T cell therapy in multiple myeloma, a malignant tumour disease in the bone marrow. The findings have been published in the prestigious journal Nature Cancer. CAR T cell therapy involves the collection of immune cells called T cells from the patient. These are genetically modified in the laboratory to carry a receptor on their surface. This receptor enables the immune cell to recognise the cancer cells and initiate their destruction. Despite impressive clinical results, some patients do not respond to CAR T cell therapy. For the…